Discovery: Exporting a Business Model Instead of a Product

Discovery is South Africa’s most successful export of a business model rather than a product. This story covers Adrian Gore’s founding, Vitality, the shared-value theory, the international licensing, Discovery Bank and the execution risks — part of the South Africa Company Stories hub.

How did Discovery begin?

Adrian Gore founded it in 1992 with modest capital and a team from Rand Merchant Bank’s orbit, entering health insurance administration in a South African market undergoing regulatory change that created space for new entrants.

The founding insight was that health insurance is not really about paying claims but about the behaviour that generates them, and that an insurer able to influence behaviour would occupy a fundamentally better position than one that merely priced risk.

Discovery Health became the largest medical scheme administrator in South Africa, managing the Discovery Health Medical Scheme and providing the customer base and data on which everything else was built.

What is the shared-value model actually claiming?

That rewarding health-improving behaviour produces measurable behaviour change, that changed behaviour reduces morbidity and therefore claims, and that the savings exceed the cost of the rewards — making the programme self-funding rather than a marketing expense.

The mechanism requires measurement. Vitality tracks gym attendance, physical activity through wearables, health screenings, nutrition purchases and driving behaviour, converting them into points that determine status, which determines rewards ranging from discounted flights to cash back on healthy food.

Discovery has published extensive research supporting the causal chain, and the model has been sufficiently persuasive to attract major international insurers as licensees — though independent verification of the full effect size remains a subject of academic debate.

Why does the incentive structure work?

Because it aligns three parties who normally conflict. The insurer wants lower claims, the member wants lower premiums and better health, and partner businesses want customers — and the programme routes value between them so that each gets something from the same behaviour.

Partner funding is the underappreciated element. Gyms, airlines, retailers and food producers pay to participate because Vitality delivers them engaged customers, which means Discovery funds a substantial part of the rewards from partners rather than from premiums.

Status levels create the engagement mechanism. Progression through tiers produces the same behavioural pull that airline frequent flyer programmes generate, applied to activity that genuinely benefits the person doing it.

How did international expansion work?

Through licensing and joint ventures rather than through owned operations. Discovery partnered with established insurers — John Hancock in the United States, Generali in Europe, Ping An in China, AIA in Asia, Vitality in the United Kingdom — providing the model, technology and expertise while partners provided licences, capital and distribution.

This is an intellectual property business rather than an insurance business. Discovery earns fees, shares of profit and equity participations without carrying the full capital requirements or regulatory obligations of underwriting in twenty countries.

It is also a genuinely unusual South African achievement: exporting a management system and behavioural science platform to sophisticated developed-market insurers who had every opportunity to build their own.

Why launch a bank?

Because behavioural incentives apply to money as well as to health. Discovery Bank, launched in 2019, applies Vitality logic to financial behaviour — rewarding customers for managing debt, saving, spending within means and improving credit health with better interest rates and rewards.

The strategic thesis is that financial behaviour, like health behaviour, drives risk, and that a bank able to improve customer behaviour holds a better credit book than one that merely prices existing risk.

Execution has been capital-intensive and slower than planned. Building a bank from nothing requires enormous technology investment and years of customer acquisition, and the venture consumed group capital through a period when investors would have preferred returns.

What are the execution risks?

Complexity, capital and concentration. The group runs health administration, life insurance, short-term insurance, investments, a bank and an international licensing business, each with different economics, regulators and capital requirements.

South African medical scheme regulation is a specific risk: Discovery Health administers a scheme it does not own, under a regulatory framework subject to reform proposals including National Health Insurance that could fundamentally alter the private healthcare market.

The group also carries substantial investment in future business — new ventures, international expansion, technology — which depresses current earnings and requires investors to accept a long-horizon story in a market that generally does not.

What would National Health Insurance mean?

Potentially a fundamental restructuring of private healthcare. Proposals for a single-payer system funded through taxation would change the role of medical schemes substantially, with implications for administrators whose business depends on them.

Implementation faces enormous fiscal, capacity and legal obstacles, and the timeline is uncertain, but the policy direction creates genuine strategic uncertainty for the entire private health sector.

Discovery’s diversification — into life, short-term insurance, banking and international licensing — is partly a response to this concentration risk, which is a rational reason for complexity that investors sometimes read as empire building.

What is the lesson from Discovery?

That business model innovation can be a more valuable export than product. Discovery built a system, proved it worked, documented the evidence and sold it to companies far larger than itself — an approach available to any firm that solves a genuine problem rigorously enough to demonstrate it.

The second lesson concerns incentive design. The programme works because it aligns parties whose interests normally conflict and because it makes the behaviour it wants measurable and rewarded immediately rather than eventually.

The third is about founder-led long-horizon investment. Discovery’s repeated willingness to fund new ventures through years of losses reflects founder conviction and control, and it is the reason both the international business and the bank exist — a pattern examined across founders in the South African founders coverage.

How is Vitality actually measured?

Through verified data rather than self-reporting. Gym attendance is recorded at the door, physical activity through connected devices, health screenings through accredited providers, and food purchases through partner retailer transaction data.

Verification is what makes the model work. A rewards programme based on claimed behaviour would be gamed immediately; one based on measured behaviour produces data the insurer can actually price against and research that can be published credibly.

It also produces a substantial proprietary dataset on the relationship between measured behaviour and health outcomes, which is the underlying asset that international insurers are licensing when they adopt the model.

Why did international insurers license rather than copy?

Because the model is more than a rewards programme. It requires actuarial pricing linked to behaviour, verified data infrastructure, a partner network delivering rewards, engagement design that sustains participation, and evidence sufficient to satisfy regulators that behaviour-linked pricing is fair.

Assembling those components independently would take years and might not produce a system that works, whereas licensing delivers a tested platform with documented outcomes and ongoing development.

The arrangement suits both sides: the licensee gains differentiation in a commoditized market, and Discovery earns from markets it could never have entered as an underwriter given capital and regulatory requirements.

What does the South African health business actually do?

Administers a medical scheme rather than underwriting health insurance. South African law separates medical schemes, which are member-owned non-profit entities, from the administrators that run them, so Discovery Health earns fees for administration, managed care and related services.

This structure limits underwriting profit and creates a different business: efficiency, claims management, provider negotiation and member service determine returns rather than risk selection.

It also concentrates regulatory risk. Changes to how schemes are regulated, what administrators may charge or how the private health system is structured affect the business directly, which is why health reform proposals matter so much to the group.

What is the short-term insurance business?

Discovery Insure applies the same behavioural logic to motor and household cover, measuring driving behaviour through telematics and rewarding safe driving with fuel benefits and premium advantages.

The mechanism is identical to Vitality: measure behaviour that drives claims, reward improvement, share the resulting savings. Motor insurance is particularly suited to it because driving behaviour is measurable in detail and correlates strongly with claims frequency.

Competition in South African short-term insurance is intense, with direct insurers competing hard on price, so behavioural differentiation must deliver genuinely better risk selection rather than merely a marketing story.

What does the group’s investment in new business cost?

Reported earnings, consistently. Discovery has spent heavily on the bank, international expansion and new products, which reduces current profit in exchange for future position — a trade its founder has defended repeatedly and that investors have accepted with varying patience.

The discipline this requires is honest accounting for new business investment, which the group provides through separate disclosure of established and new business performance, allowing investors to assess the core operations independently of the spending.

What is the risk if behaviour data becomes regulated?

Substantial. Behaviour-linked pricing depends on collecting and using personal health, activity and driving data, and privacy regulation, discrimination concerns and consumer protection rules all bear on whether that remains permissible in each market.

Discovery’s position is that members opt in voluntarily and receive value in exchange, and that the resulting pricing is fairer than pricing based on demographics. Regulators have broadly accepted this, though the boundary between rewarding behaviour and penalizing circumstance is genuinely contested and will be tested repeatedly.

The commercial exposure is that the model’s value depends on data flows that a single adverse regulatory decision in a major market could restrict.

How does the group think about long-horizon investment?

As the core of its strategy rather than as an occasional exception. Discovery has consistently funded ventures that take years to reach profitability — international licensing, the bank, new product categories — on the basis that its competitive position depends on building things competitors cannot quickly copy.

That posture requires shareholder tolerance and founder conviction in roughly equal measure, and it is the clearest explanation for both the group’s distinctive assets and its periodic disappointment of investors expecting near-term returns.

Frequently Asked Questions